Health & Environmental Research Online (HERO)


Print Feedback Export to File
7336132 
Journal Article 
Precision medicine in oncology II: Economics of targeted agents and immuno-oncology drugs 
Huntington, SF; Davidoff, AJ; Gross, CP 
2020 
Yes 
Journal of Clinical Oncology
ISSN: 0732-183X
EISSN: 1527-7755 
American Society of Clinical Oncology 
38 
4 
351-358 
English 
Unlike the formidable biologic barriers to fully realizing the clinical benefits of precision oncology, economic challenges are within our collective ability to address through renewed investment in clinical trials that produce actionable data and innovative health care policy and regulatory science. However, many stakeholders are faring quite well under the current system of developing and delivering TA/IO drugs - including the pharmaceutical industry, pharmacy benefit managers, commercial US payers, and many US providers and hospital systems - leading to considerable resistance to making necessary policy changes. Unfortunately, the stakeholders at greatest financial risk - patients and families - have the least influence to enact change. Time is of the essence to develop the evidence base to inform health policy and regulatory science that fosters a system where patients with cancer have affordable and equitable access to innovative therapies in the era of precision oncology. © 2019 by American Society of Clinical Oncology. 
cancer research; cost; downstream processing; drug approval; drug research; economic aspect; ecosystem; high income country; human; oncology; personalized medicine; priority journal; Review; United States; economics; financial management; immunotherapy; molecularly targeted therapy; neoplasm; oncology; personalized medicine; procedures; immunological antineoplastic agent; Antineoplastic Agents, Immunological; Humans; Immunotherapy; Marketing of Health Services; Medical Oncology; Molecular Targeted Therapy; Neoplasms; Precision Medicine; United States